MBX Biosciences presents safety, pharmacokinetics data at ADA Scientific Sessions.

MBX Biosciences is presenting at the American Diabetes Association's 85th Scientific Sessions. Two posters will showcase the safety, pharmacokinetics, and pharmacodynamics of MBX 1416, a glucagon-like peptide-1 receptor antagonist, in healthy volunteers and rats. The findings demonstrate the mechanism of action of MBX 1416 and its potential as a treatment for endocrine and metabolic disorders.

MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company, is set to present its latest research on MBX 1416 at the American Diabetes Association's (ADA) 85th Scientific Sessions, scheduled for June 20-23, 2025, in Chicago, IL. The company will showcase two posters detailing the safety, pharmacokinetics, and pharmacodynamics of MBX 1416, a glucagon-like peptide-1 (GLP-1) receptor antagonist, in healthy volunteers and rats.

Poster Presentations:

- 846-P - Safety, Pharmacokinetics, and Pharmacodynamics of MBX 1416 in Healthy Volunteers: Presented by Elisa Fabbrini, MD, PhD, this poster will discuss the results of a Phase 1 randomized trial. The study investigated the safety and efficacy of MBX 1416 in healthy adult volunteers [1].
- 845-P - MBX 1416 Elevates and Sustains Blood Glucose in Rats: Presented by Richard DiMarchi, PhD, this poster will highlight the findings from a study in rats, demonstrating the ability of MBX 1416 to elevate and sustain blood glucose levels without changes in body weight. This study underscores the potential of MBX 1416 as a treatment for post-bariatric hypoglycemia (PBH) [1].

MBX 1416 and Post-Bariatric Hypoglycemia:

MBX 1416 is an investigational long-acting GLP-1 receptor antagonist designed to prevent severe hypoglycemia in individuals with PBH. PBH is a rare and serious complication of bariatric surgery, characterized by repeated episodes of symptomatic hypoglycemia triggered by exaggerated secretion of GLP-1 levels following a meal. The unpredictability of hypoglycemic episodes can significantly hinder daily activities and quality of life for patients [1].

Market Implications:

The findings presented at the ADA's Scientific Sessions could pave the way for MBX 1416 to become a safe and effective therapy for PBH. As the incidence of PBH is expected to rise with the increasing use of bariatric surgery for metabolic conditions, the need for effective treatments is growing. Successful clinical trials and regulatory approvals could expand the market for MBX Biosciences and its pipeline of precision peptide therapies [1].

References:

[1] https://www.globenewswire.com/news-release/2025/06/10/3096537/0/en/MBX-Biosciences-to-Present-at-the-American-Diabetes-Association-85th-Scientific-Sessions.html